Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results
Cancer
 

Click here to go back to your search results.

Lung Cancer treatment details. Biologic therapy. Chemotherapy. Service de Pneumologie, Draguignan, France



Survival: 4.4 months
   
Toxicity Grade: 4
   
Treatments: Biologic therapy
Chemotherapy
   
Drugs:
Country: France
   
City/State/Province: Draguignan
   
Hospital: Service de Pneumologie
   
Journal: Link
   
Date: 7/2012

Description:
Patients:
This phase II study involved 44 elderly advanced non-small-cell lung cancer patients with an average age of 78.2 years; 84.1% were male.

Treatment:
Patients were treated with the chemotherapy agent gemcitabine and the biologic therapy agent erlotinib, which is a small molecule inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, which is involved in cell growth and survival.

Toxicities:
The most severe treatment-related toxicities included grade 3-4 weakness, anemia, and thrombocytopenia. Grade 1-2 skin reactions were also reported.

Results:
The median overall survival was 4.4 months.

Support:
This study was supported by the pharmaceutical companies Roche, Lilly, and Sanofi-Aventis.

Correspondence: Dr. Herve LeCaer; email: herve.lecaer@ch-draguignan.fr

E-mail to a Friend Email Physician More Information